---
title: "Merck Scores Positive Feedback From EU Regarding Cancer Drug"
description: "On Friday, a European agency adopted two positive opinions for Merck & Co. Inc.'s MRK Keytruda ( pembrolizumab ) . One opinion recommends approval of a new subcutaneous ( SC ) administration route and"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258143867.md"
published_at: "2025-09-19T20:01:48.000Z"
---

# Merck Scores Positive Feedback From EU Regarding Cancer Drug

> On Friday, a European agency adopted two positive opinions for Merck & Co. Inc.'s MRK Keytruda ( pembrolizumab ) . One opinion recommends approval of a new subcutaneous ( SC ) administration route and a solution for injection formulation.

On Friday, a European agency adopted two positive opinions for Merck & Co. Inc.'s MRK Keytruda ( pembrolizumab ) . One opinion recommends approval of a new subcutaneous ( SC ) administration route and a solution for injection formulation.

### Related Stocks

- [MRK.US - Merck](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 默克獲得 FDA 批准，Keytruda 聯合療法用於治療卵巢癌 | 默沙東已獲得 FDA 批准，將 Keytruda 和 Keytruda Qlex 與紫杉醇聯合用於治療鉑耐藥性卵巢癌。該批准基於 III 期 KEYNOTE-B96 試驗數據，顯示 PD-L1 表達腫瘤患者在無進展生存期和總體生存期方面有顯 | [Link](https://longbridge.com/en/news/275742611.md) |
| 美國食品藥品監督管理局（FDA）批准安捷倫科技的 PD-L1 測試用於一線卵巢癌治療 | 安捷倫科技公司已獲得 FDA 批准，將其 PD-L1 IHC 22C3 pharmDx 作為上皮性卵巢癌、輸卵管癌或原發性腹膜癌患者一線治療的伴隨診斷工具。該測試有助於識別符合條件的患者，以接受默克的 KEYTRUDA®（帕博利珠單抗）治療 | [Link](https://longbridge.com/en/news/275522199.md) |
| 佳明有限公司（NYSE:GRMN）的空頭頭寸增加了 33.2% | 佳明有限公司（NYSE:GRMN）在 1 月份的空頭頭寸增加了 33.2%，截至 1 月 30 日，總計 3,028,012 股。這佔公司已售空股票的 2.0%，根據平均每日交易量 968,298 股，覆蓋天數比率為 3.1 天。此外，內部 | [Link](https://longbridge.com/en/news/276018254.md) |
| 期權熱點｜上周五 NBIS 大漲 9%，部分看漲期權飆升 378% | 美東時間 2026-02-13，Nebius 期權總成交 179098 張，看漲期權佔比 71%，看跌期權佔比 28%。 | [Link](https://longbridge.com/en/news/276030151.md) |
| Codeifai 進入由 AI 支持的量子安全市場 | Codeifai Ltd：CODEIFAI 進入人工智能支持的量子安全市場，完成對 AntennaTransfer.Io 的收購，總對價為 130 萬澳元 | [Link](https://longbridge.com/en/news/276015719.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.